Fundraising Fox
Advanced Nanotherapies
Cleveland, US · Founded 2018 · Delaware corporation · 21 employees on LinkedIn · 1 known investors
Find your way into Advanced Nanotherapies
Sign up to see every warm intro you have to Advanced Nanotherapies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Advanced Nanotherapies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Advanced NanoTherapies (ANT) develops next-generation drug-coated balloons (DCBs) using nanotechnology to treat vascular disease. The company operates in the medical device and nanomedicine field, focused on cardiovascular and endovascular interventions.
Founders & leadership
Advanced Nanotherapies was founded in 2018 by Marwan Berrada-Sounni and Marwan Berrada.
MB
Marwan Berrada-SounniPresident, CEO, and co-founderMarwan Berrada-Sounni is a biomedical engineer with over 20 years in medical device product development and commercialization who co-founded and serves as CEO of Advanced NanoTherapies, which develops drug-coated balloons using nanotechnology for vascular disease treatment. He has worked on percutaneous therapies including electrophysiology, structural heart, cardiovascular, and endovascular devices, and has obtained patents and FDA approvals for medical technologies.
MB
Marwan BerradaFounderMarwan Berrada is a biomedical engineer with over 20 years of experience in medical device product development and commercialization who founded Advanced NanoTherapies, which develops drug-coated balloons using nanotechnology to treat peripheral arterial disease. He has expertise in cardiovascular and endovascular interventions and has obtained patents and FDA approvals for medical devices.
MS
Mehdi ShishehborNamed on SEC filing
JC
Jerett CreedNamed on SEC filing
RG
Regina GrovesNamed on SEC filing
PU
Phillippe UrbainNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 2 rounds · 2019–2022
▶$9.2MraisedAug 2022 · 17 investors · BiotechnologyRule 506(b)
▶$9.2MraisedAug 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mehdi ShishehborDirector
- Jerett CreedDirector
- Marwan Berrada-SounniExecutive Officer, Director
- Regina GrovesDirector
- Phillippe UrbainDirector
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- Minimum investment
- $50K
- Proceeds to insiders
- $600K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$640KraisedAug 2022 · 10 investors · BiotechnologyRule 506(b)
▶$640KraisedAug 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mehdi ShishehborDirector
- Marwan Berrada-SounniExecutive Officer, Director
- Regina GrovesDirector
- Phillippe UrbainDirector
- Jerett CreedDirector
- Offering amount
- $640K
- Amount sold
- $640K
- Minimum investment
- $4K
- Proceeds to insiders
- $250K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Advanced Nanotherapies went on to found or lead other companies.
Related companies · 3
Integrated Nanotherapeutics Inc.Integrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.
ロゴマーク：AIRNAAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Companies working in the same space as Advanced Nanotherapies.
Frequently asked questions
- What does Advanced Nanotherapies do?
- Advanced NanoTherapies (ANT) develops next-generation drug-coated balloons (DCBs) using nanotechnology to treat vascular disease. The company operates in the medical device and nanomedicine field, focused on cardiovascular and endovascular interventions.
- Who founded Advanced Nanotherapies?
- Advanced Nanotherapies was founded by Marwan Berrada-Sounni, Marwan Berrada in 2018.
- Who are Advanced Nanotherapies's investors?
- Advanced Nanotherapies's investors include S3 Ventures.
- How much funding has Advanced Nanotherapies raised?
- Advanced Nanotherapies has disclosed $9.9M raised across 2 rounds.
- Where is Advanced Nanotherapies headquartered?
- Advanced Nanotherapies is headquartered in Cleveland, US.